X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12202) 12202
Book Review (2783) 2783
Publication (892) 892
Book Chapter (73) 73
Newsletter (48) 48
Book / eBook (21) 21
Conference Proceeding (20) 20
Dissertation (12) 12
Magazine Article (8) 8
Paper (4) 4
Data Set (3) 3
Reference (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10864) 10864
humans (7647) 7647
male (6569) 6569
animals (4647) 4647
female (4339) 4339
hypertrophy (3855) 3855
hypertension (3621) 3621
cardiac & cardiovascular systems (3489) 3489
middle aged (3427) 3427
left-ventricular hypertrophy (3203) 3203
hypertension - drug therapy (2786) 2786
rats (2722) 2722
aged (2367) 2367
peripheral vascular disease (2249) 2249
heart (2099) 2099
adult (2036) 2036
echocardiography (2028) 2028
heart failure (1957) 1957
hypertension - physiopathology (1835) 1835
antihypertensive agents - therapeutic use (1820) 1820
risk factors (1753) 1753
hypertension - complications (1642) 1642
blood pressure - drug effects (1569) 1569
pharmacology & pharmacy (1555) 1555
blood pressure (1524) 1524
heart-failure (1514) 1514
hypertrophy, left ventricular - drug therapy (1499) 1499
cardiac-hypertrophy (1458) 1458
abridged index medicus (1448) 1448
hypertrophy, left ventricular - physiopathology (1407) 1407
left ventricular hypertrophy (1398) 1398
blood-pressure (1362) 1362
hypertrophy, left ventricular - etiology (1239) 1239
mortality (1211) 1211
disease models, animal (1134) 1134
mice (1122) 1122
treatment outcome (1107) 1107
cardiology (1096) 1096
myocardium - pathology (1087) 1087
fibrosis (1034) 1034
physiology (973) 973
cardiomyopathy (944) 944
myocardial-infarction (934) 934
angiotensin-converting enzyme inhibitors - therapeutic use (930) 930
myocardium - metabolism (929) 929
rodents (923) 923
time factors (913) 913
cardiovascular disease (881) 881
disease (878) 878
heart diseases (870) 870
urology & nephrology (865) 865
rats, sprague-dawley (860) 860
electrocardiography (837) 837
research (829) 829
oxidative stress (825) 825
hypertrophy, left ventricular - diagnostic imaging (789) 789
medicine & public health (783) 783
expression (780) 780
prognosis (773) 773
analysis (772) 772
cardiovascular (756) 756
health aspects (751) 751
physiological aspects (743) 743
heart enlargement (741) 741
care and treatment (740) 740
cardiac hypertrophy (719) 719
drug therapy (694) 694
cell biology (690) 690
cardiovascular diseases (681) 681
heart failure - physiopathology (676) 676
prospective studies (669) 669
follow-up studies (663) 663
mass (661) 661
hypertrophy, left ventricular - complications (655) 655
heart failure - drug therapy (653) 653
dysfunction (650) 650
rats, wistar (647) 647
ventricular function, left - drug effects (630) 630
gene expression (625) 625
prevalence (621) 621
apoptosis (610) 610
angiotensin (602) 602
therapy (599) 599
ventricular remodeling - drug effects (598) 598
medicine, research & experimental (593) 593
cardiovascular system (582) 582
ventricle (577) 577
proteins (575) 575
medicine, general & internal (566) 566
heart - drug effects (563) 563
article (557) 557
risk (552) 552
medicine (544) 544
hemodynamics - drug effects (532) 532
hypertrophy, left ventricular - pathology (529) 529
myocytes, cardiac - drug effects (528) 528
rats, inbred shr (518) 518
hypertrophy, left ventricular - prevention & control (512) 512
angiotensin-ii (510) 510
diabetes (508) 508
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11867) 11867
German (105) 105
Russian (92) 92
Spanish (75) 75
French (55) 55
Chinese (35) 35
Italian (29) 29
Japanese (22) 22
Portuguese (15) 15
Polish (12) 12
Hungarian (7) 7
Ukrainian (5) 5
Danish (4) 4
Bosnian (3) 3
Slovak (3) 3
Dutch (2) 2
Korean (2) 2
Norwegian (2) 2
Swedish (2) 2
Croatian (1) 1
Czech (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 02/2012, Volume 307, Issue 7, pp. 674 - 684
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2009, Volume 54, Issue 6, pp. 505 - 512
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 01/2014, Volume 25, Issue 1, pp. 175 - 186
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 10/2003, Volume 108, Issue 15, pp. 1831 - 1838
Background - Elevated renin-angiotensin-aldosterone system activity correlates with left ventricular hypertrophy (LVH) and cardiovascular risk, but the... 
Hypertension | Blood pressure | Ventricles | Hypertrophy | blood pressure | CARDIAC & CARDIOVASCULAR SYSTEMS | hypertrophy | LOSARTAN INTERVENTION | CARDIOVASCULAR MORBIDITY | ANGIOTENSIN-CONVERTING ENZYME | BLOOD-PRESSURE | ventricles | RANDOMIZED TRIAL | END-POINT REDUCTION | MYOCARDIAL FIBROSIS | PERIPHERAL VASCULAR DISEASE | ALDOSTERONE | SUPEROXIDE PRODUCTION | HEMATOLOGY | hypertension | SMOOTH-MUSCLE CELLS | Spironolactone - administration & dosage | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Enalapril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adult | Female | Hypertrophy, Left Ventricular - drug therapy | Spironolactone - analogs & derivatives | Drug Therapy, Combination | Enalapril - administration & dosage | Amlodipine - administration & dosage | Spironolactone - therapeutic use | Mineralocorticoid Receptor Antagonists - administration & dosage | Double-Blind Method | Myocardium - pathology | Renin-Angiotensin System - physiology | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Hypertension - physiopathology | Amlodipine - therapeutic use | Mineralocorticoid Receptor Antagonists - therapeutic use | Drug Synergism | Magnetic Resonance Imaging | Potassium - blood | Renin-Angiotensin System - drug effects | Aged | Hypertrophy, Left Ventricular - physiopathology | Hydrochlorothiazide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 02/2009, Volume 119, Issue 4, pp. 530 - 537
Background-Left ventricular (LV) hypertrophy, a marker of cardiac end-organ damage, is associated with an increased risk of cardiovascular morbidity and... 
Hypertension | Renin | Magnetic resonance imaging | Angiotensin | Hypertrophy | PROGNOSTIC IMPLICATIONS | magnetic resonance imaging | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | EFFICACY | hypertrophy | SAFETY | HEART-FAILURE | RANDOMIZED-TRIAL | BLOOD-PRESSURE | IMPACT | REDUCTION | renin | angiotensin | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | hypertension | INTERVENTION | Angiotensin II Type 1 Receptor Blockers - adverse effects | Echocardiography | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Fumarates - administration & dosage | Hypertension - drug therapy | Male | Treatment Outcome | Fumarates - adverse effects | Antihypertensive Agents - adverse effects | Magnetic Resonance Imaging | Hypertrophy, Left Ventricular - pathology | Amides - adverse effects | Losartan - adverse effects | Female | Aged | Blood Pressure - drug effects | Hypertrophy, Left Ventricular - drug therapy | Losartan - administration & dosage | Drug Therapy, Combination | Amides - administration & dosage | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Hypertrophy, Left Ventricular - diagnostic imaging | Heart enlargement | Angiotensin II receptor blockers | Physiological aspects | Dosage and administration | Research | Drug therapy | Comparative analysis | Renin-angiotensin system | ACE inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 2007, Volume 116, Issue 7, pp. 700 - 705
Background - Sudden cardiac death ( SCD) occurs more often in patients with ECG left ventricular ( LV) hypertrophy. However, whether LV hypertrophy regression... 
Hypertension | Electrocardiography | Death, sudden | Mortality | Hypertrophy | ARRHYTHMIAS | CARDIAC & CARDIOVASCULAR SYSTEMS | hypertrophy | CARDIOVASCULAR EVENTS | RISK | LOSARTAN INTERVENTION | electrocardiography | END-POINT REDUCTION | MORBIDITY | MASS | mortality | PERIPHERAL VASCULAR DISEASE | ESSENTIAL-HYPERTENSION | death,sudden | hypertension | ASSOCIATION | Hypertrophy, Left Ventricular - mortality | Double-Blind Method | Death, Sudden, Cardiac - epidemiology | Humans | Middle Aged | Death, Sudden, Cardiac - prevention & control | Hypertension - drug therapy | Male | Death, Sudden, Cardiac - etiology | Antihypertensive Agents - therapeutic use | Atenolol - therapeutic use | Hypertrophy, Left Ventricular - complications | Losartan - therapeutic use | Aged, 80 and over | Hypertension - complications | Female | Aged | Hypertrophy, Left Ventricular - drug therapy | Hypertension - diagnosis | Prevention | Care and treatment | Usage | Heart enlargement | Electrocardiogram | Cardiac arrest | Diagnosis | Research | Index Medicus | Abridged Index Medicus | Antihypertensive Agents/therapeutic use | Hypertrophy; Left Ventricular/complications/drug therapy/mortality | Aged; 80 and over | Losartan/therapeutic use | Hypertension/complications/diagnosis/drug therapy | Death; Sudden; Cardiac/epidemiology/etiology/prevention & control | Atenolol/therapeutic use
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 09/2004, Volume 110, Issue 11, pp. 1456 - 1462
Background-An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of... 
Hypertension | Echocardiography | Controlled clinical trials | Hypertrophy, left ventricular | Angiotensin | PROGNOSTIC IMPLICATIONS | CARDIAC & CARDIOVASCULAR SYSTEMS | ECHOCARDIOGRAPHIC MEASUREMENTS | METAANALYSIS | controlled clinical trials | echocardiography | hypertrophy, left ventricular | RISK | MORBIDITY | MASS | angiotensin | PERIPHERAL VASCULAR DISEASE | hypertension | SERIAL CHANGES | ASSOCIATION | AMBULATORY BLOOD-PRESSURE | GEOMETRY | Prospective Studies | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Hypertension - drug therapy | Male | Heart Ventricles - diagnostic imaging | Heart Rate - drug effects | Ultrasonography | Aged, 80 and over | Female | Blood Pressure - drug effects | Hypertrophy, Left Ventricular - drug therapy | Heart Ventricles - pathology | Adrenergic beta-Antagonists - therapeutic use | Double-Blind Method | Hypertrophy, Left Ventricular - etiology | Organ Size | Treatment Outcome | Antihypertensive Agents - therapeutic use | Atenolol - therapeutic use | Losartan - therapeutic use | Hypertension - complications | Aged | Heart Ventricles - drug effects | Hypertrophy, Left Ventricular - diagnostic imaging | Index Medicus | Abridged Index Medicus | Antihypertensive Agents/therapeutic use | Angiotensin II Type 1 Receptor Blockers/therapeutic use | Heart Ventricles/drug effects/pathology/ultrasonography | Adrenergic beta-Antagonists/therapeutic use | Hypertrophy; Left Ventricular/drug therapy/etiology/ultrasonography | Blood Pressure/drug effects | Heart Rate/drug effects | Hypertension/complications/drug therapy | Aged; 80 and over | Losartan/therapeutic use | Atenolol/therapeutic use
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2005, Volume 45, Issue 5, pp. 712 - 719
Journal Article
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 08/2013, Volume 305, Issue 3, pp. H295 - H304
Glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is a remedy for type 2 diabetes mellitus (T2DM). Ex-4 ameliorates cardiac dysfunction... 
Oxidative stress | Insulin resistance | Glucagon-like peptide-1 | Mitochondria | Diabetes mellitus | CARDIAC & CARDIOVASCULAR SYSTEMS | PHYSIOLOGY | MYOCARDIAL-INFARCTION | mitochondria | glucagon-like peptide-1 | CARDIOMYOPATHY | diabetes mellitus | INSULIN SENSITIVITY | HEART | OBESITY | LEFT-VENTRICULAR DYSFUNCTION | INFLAMMATION | MOUSE MODEL | MITOCHONDRIAL DYSFUNCTION | PERIPHERAL VASCULAR DISEASE | MICE | insulin resistance | oxidative stress | Mitochondria, Heart - metabolism | Diabetic Cardiomyopathies - drug therapy | Mitochondria, Heart - pathology | NADPH Oxidases - metabolism | Male | Diabetic Cardiomyopathies - physiopathology | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Time Factors | Ventricular Dysfunction, Left - blood | Diet, High-Fat | Myocardium - metabolism | Diabetic Cardiomyopathies - blood | Disease Models, Animal | Receptors, Glucagon - agonists | Glutathione Peroxidase - metabolism | Ventricular Function, Left - drug effects | Hypoglycemic Agents - pharmacology | Intercellular Adhesion Molecule-1 - metabolism | Glucagon-Like Peptide-1 Receptor | Fibrosis | Mice | Hypertrophy, Left Ventricular - physiopathology | Oxidative Stress - drug effects | Diabetes Mellitus, Type 2 - genetics | Mitochondria, Heart - drug effects | Dyslipidemias - blood | Echocardiography, Doppler | Inflammation Mediators - metabolism | Venoms - administration & dosage | Hypertrophy, Left Ventricular - drug therapy | Superoxide Dismutase - metabolism | Diabetic Cardiomyopathies - diagnostic imaging | Dyslipidemias - drug therapy | Hypertrophy, Left Ventricular - blood | Insulin Resistance | Receptors, Glucagon - metabolism | Myocardium - pathology | Macrophage Colony-Stimulating Factor - metabolism | NADPH Oxidase 4 | Ventricular Dysfunction, Left - physiopathology | Infusions, Subcutaneous | Peptides - pharmacology | Diabetes Mellitus, Type 2 - blood | Animals | Ventricular Dysfunction, Left - drug therapy | Lipid Metabolism - drug effects | Venoms - pharmacology | Superoxide Dismutase-1 | Diabetes Mellitus, Type 2 - drug therapy | Ventricular Remodeling - drug effects | Type 2 diabetes | Physiological aspects | Peptides | Health aspects | Heart attack | Heart attacks | Cytokines | Rodents | Lipids | Index Medicus
Journal Article